Affimed (AFMD) Set to Announce Earnings on Thursday

Affimed (NASDAQ:AFMD) is scheduled to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter.

Affimed (NASDAQ:AFMD) last announced its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Affimed Price Performance

AFMD stock opened at $3.69 on Thursday. The business has a 50-day moving average of $3.53 and a 200-day moving average of $4.58. Affimed has a fifty-two week low of $2.92 and a fifty-two week high of $8.95. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AFMD. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Affimed in a research report on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Affimed currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.